rs1204329 - RNU4-66P - RIMS1
Magnitude 2.2 · 1 study on file
Reported associations
-
Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. - Nature genetics (2022) · Watanabe K, Jansen PR, Savage JE, Nandakumar P, Wang X, Hinds DA, Gelernter J, Levey DF, Polimanti R, Stein MB, Van Someren EJW, Smit AB, Posthuma D · PubMed 35835914
Insomnia is a heritable, highly prevalent sleep disorder for which no sufficient treatment currently exists. Previous genome-wide association studies with up to 1.3 million subjects identified over 200 associated loci. This extreme polygenicity suggested that many more loci remain to be discovered. The current study almost doubled the sample size to 593,724 cases and 1,771,286 controls, thereby increasing statistical power, and identified 554 risk loci (including 364 novel loci). To capitalize on this large number of loci, we propose a novel strategy to prioritize genes using external biological resources and functional interactions between genes across risk loci. Of all 3,898 genes naively implicated from the risk loci, we prioritize 289 and find brain-tissue expression spec
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
insomnia risk assessment with physician Moderate
Genetic association identifies increased baseline risk; clinical assessment helps inform prevention strategies or early intervention if symptoms emerge
Discuss sleep quality and any sleep disturbances at routine clinical visit
Lifestyle
-
sleep quality monitoring and optimization Moderate
Risk allele (A) associated with increased insomnia in meta-analysis of 2.36M individuals; RIMS1 regulates synaptic neurotransmitter release affecting sleep regulation
Maintain consistent sleep schedule; track sleep duration and quality daily